Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: Retrospective survey involving 256 patients in Japan

T. Matsumura, M. Kami, T. Yamaguchi, K. Yuji, E. Kusumi, S. Taniguchi, S. Takahashi, M. Okada, H. Sakamaki, H. Azuma, M. Takanashi, H. Kodo, S. Kai, T. Inoue-Nagamura, K. Kato, S. Kato

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

We investigated the efficacy of cord blood transplantation (CBT) for adult acute lymphoblastic leukemia (ALL) by reviewing medical records of 256 patients reported to the Japan Cord Blood Bank Network between June 1997 and August 2006. Cumulative incidence of neutrophil engraftment at day 100 was 78%. Infused CD34-positive cell dose (1 × 10 5 cells/kg) was associated with successful neutrophil engraftment. Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 was 37%. A 2-year disease-free and overall survival (OS) rates were 36% and 42%, respectively. Multivariate analysis showed that age (51 or older vs younger than 50) (hazard ratio 1.9, 95% confidence interval (CI), 1.3-2.8, P0.001), disease status (non-remission vs remission) (hazard ratio 2.2, 95% CI, 1.5-3.2, P0.0001), grade III-IV acute GVHD (hazard ratio 2.0, 95% CI, 1.2-3.2, P0.006) and absence of chronic GVHD (hazard ratio 2.4, 95% CI, 1.1-5.1, P0.02) were negatively associated with OS. CBT is effective for some patients with advanced ALL. It is worth considering for further evaluation.

Original languageEnglish
Pages (from-to)1482-1486
Number of pages5
JournalLeukemia
Volume26
Issue number7
DOIs
Publication statusPublished - Jul 1 2012
Externally publishedYes

Fingerprint

Fetal Blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Japan
Graft vs Host Disease
Transplantation
Confidence Intervals
Neutrophils
Blood Banks
Incidence
Disease-Free Survival
Medical Records
Multivariate Analysis
Survival Rate
Survival
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Matsumura, T., Kami, M., Yamaguchi, T., Yuji, K., Kusumi, E., Taniguchi, S., ... Kato, S. (2012). Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: Retrospective survey involving 256 patients in Japan. Leukemia, 26(7), 1482-1486. https://doi.org/10.1038/leu.2012.11

Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia : Retrospective survey involving 256 patients in Japan. / Matsumura, T.; Kami, M.; Yamaguchi, T.; Yuji, K.; Kusumi, E.; Taniguchi, S.; Takahashi, S.; Okada, M.; Sakamaki, H.; Azuma, H.; Takanashi, M.; Kodo, H.; Kai, S.; Inoue-Nagamura, T.; Kato, K.; Kato, S.

In: Leukemia, Vol. 26, No. 7, 01.07.2012, p. 1482-1486.

Research output: Contribution to journalReview article

Matsumura, T, Kami, M, Yamaguchi, T, Yuji, K, Kusumi, E, Taniguchi, S, Takahashi, S, Okada, M, Sakamaki, H, Azuma, H, Takanashi, M, Kodo, H, Kai, S, Inoue-Nagamura, T, Kato, K & Kato, S 2012, 'Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: Retrospective survey involving 256 patients in Japan', Leukemia, vol. 26, no. 7, pp. 1482-1486. https://doi.org/10.1038/leu.2012.11
Matsumura, T. ; Kami, M. ; Yamaguchi, T. ; Yuji, K. ; Kusumi, E. ; Taniguchi, S. ; Takahashi, S. ; Okada, M. ; Sakamaki, H. ; Azuma, H. ; Takanashi, M. ; Kodo, H. ; Kai, S. ; Inoue-Nagamura, T. ; Kato, K. ; Kato, S. / Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia : Retrospective survey involving 256 patients in Japan. In: Leukemia. 2012 ; Vol. 26, No. 7. pp. 1482-1486.
@article{ae41f00aafa44f8ea704f52e304166ba,
title = "Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: Retrospective survey involving 256 patients in Japan",
abstract = "We investigated the efficacy of cord blood transplantation (CBT) for adult acute lymphoblastic leukemia (ALL) by reviewing medical records of 256 patients reported to the Japan Cord Blood Bank Network between June 1997 and August 2006. Cumulative incidence of neutrophil engraftment at day 100 was 78{\%}. Infused CD34-positive cell dose (1 × 10 5 cells/kg) was associated with successful neutrophil engraftment. Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 was 37{\%}. A 2-year disease-free and overall survival (OS) rates were 36{\%} and 42{\%}, respectively. Multivariate analysis showed that age (51 or older vs younger than 50) (hazard ratio 1.9, 95{\%} confidence interval (CI), 1.3-2.8, P0.001), disease status (non-remission vs remission) (hazard ratio 2.2, 95{\%} CI, 1.5-3.2, P0.0001), grade III-IV acute GVHD (hazard ratio 2.0, 95{\%} CI, 1.2-3.2, P0.006) and absence of chronic GVHD (hazard ratio 2.4, 95{\%} CI, 1.1-5.1, P0.02) were negatively associated with OS. CBT is effective for some patients with advanced ALL. It is worth considering for further evaluation.",
author = "T. Matsumura and M. Kami and T. Yamaguchi and K. Yuji and E. Kusumi and S. Taniguchi and S. Takahashi and M. Okada and H. Sakamaki and H. Azuma and M. Takanashi and H. Kodo and S. Kai and T. Inoue-Nagamura and K. Kato and S. Kato",
year = "2012",
month = "7",
day = "1",
doi = "10.1038/leu.2012.11",
language = "English",
volume = "26",
pages = "1482--1486",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia

T2 - Retrospective survey involving 256 patients in Japan

AU - Matsumura, T.

AU - Kami, M.

AU - Yamaguchi, T.

AU - Yuji, K.

AU - Kusumi, E.

AU - Taniguchi, S.

AU - Takahashi, S.

AU - Okada, M.

AU - Sakamaki, H.

AU - Azuma, H.

AU - Takanashi, M.

AU - Kodo, H.

AU - Kai, S.

AU - Inoue-Nagamura, T.

AU - Kato, K.

AU - Kato, S.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - We investigated the efficacy of cord blood transplantation (CBT) for adult acute lymphoblastic leukemia (ALL) by reviewing medical records of 256 patients reported to the Japan Cord Blood Bank Network between June 1997 and August 2006. Cumulative incidence of neutrophil engraftment at day 100 was 78%. Infused CD34-positive cell dose (1 × 10 5 cells/kg) was associated with successful neutrophil engraftment. Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 was 37%. A 2-year disease-free and overall survival (OS) rates were 36% and 42%, respectively. Multivariate analysis showed that age (51 or older vs younger than 50) (hazard ratio 1.9, 95% confidence interval (CI), 1.3-2.8, P0.001), disease status (non-remission vs remission) (hazard ratio 2.2, 95% CI, 1.5-3.2, P0.0001), grade III-IV acute GVHD (hazard ratio 2.0, 95% CI, 1.2-3.2, P0.006) and absence of chronic GVHD (hazard ratio 2.4, 95% CI, 1.1-5.1, P0.02) were negatively associated with OS. CBT is effective for some patients with advanced ALL. It is worth considering for further evaluation.

AB - We investigated the efficacy of cord blood transplantation (CBT) for adult acute lymphoblastic leukemia (ALL) by reviewing medical records of 256 patients reported to the Japan Cord Blood Bank Network between June 1997 and August 2006. Cumulative incidence of neutrophil engraftment at day 100 was 78%. Infused CD34-positive cell dose (1 × 10 5 cells/kg) was associated with successful neutrophil engraftment. Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 was 37%. A 2-year disease-free and overall survival (OS) rates were 36% and 42%, respectively. Multivariate analysis showed that age (51 or older vs younger than 50) (hazard ratio 1.9, 95% confidence interval (CI), 1.3-2.8, P0.001), disease status (non-remission vs remission) (hazard ratio 2.2, 95% CI, 1.5-3.2, P0.0001), grade III-IV acute GVHD (hazard ratio 2.0, 95% CI, 1.2-3.2, P0.006) and absence of chronic GVHD (hazard ratio 2.4, 95% CI, 1.1-5.1, P0.02) were negatively associated with OS. CBT is effective for some patients with advanced ALL. It is worth considering for further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=84863783753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863783753&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.11

DO - 10.1038/leu.2012.11

M3 - Review article

C2 - 22290068

AN - SCOPUS:84863783753

VL - 26

SP - 1482

EP - 1486

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -